These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15903057)

  • 1. [Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus].
    Schumm-Draeger PM
    MMW Fortschr Med; 2005 Apr; 147(17):32-4, 36. PubMed ID: 15903057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [2-year data of large clinical comparative studies. Type 2 diabetes: lasting metabolic control with pioglitazone].
    MMW Fortschr Med; 2004 Jul; 146(29-30):48-9. PubMed ID: 15540563
    [No Abstract]   [Full Text] [Related]  

  • 3. [Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus].
    Onuchin SG; Elsukova OS; Solov'ev OV; Onuchina EL
    Ter Arkh; 2010; 82(8):34-41. PubMed ID: 20873243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus.
    Erem C; Ozbas HM; Nuhoglu I; Deger O; Civan N; Ersoz HO
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):295-302. PubMed ID: 24710641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Warning signals insulin resistance. Insulin resistance causes not only diabetes].
    MMW Fortschr Med; 2004 Jul; 146(29-30):49. PubMed ID: 15540564
    [No Abstract]   [Full Text] [Related]  

  • 7. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Standl E; Schnell O
    Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pharmacological recommendations in the daily metabolic control of diabetes mellitus type 2. The role of the new insulins].
    Sánchez Sánchez O; Sabán Ruiz J
    Rev Clin Esp; 2007 Sep; 207(8):411-5. PubMed ID: 17688872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone and sulfonylureas: effectively treating type 2 diabetes.
    Hanefeld M
    Int J Clin Pract Suppl; 2007 Jun; 61(153):20-7. PubMed ID: 17594390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pioglitazone/metformin (Actoplus met).
    Med Lett Drugs Ther; 2006 Jan; 48(1227):9-11. PubMed ID: 16444136
    [No Abstract]   [Full Text] [Related]  

  • 11. [Metabolic and hemodynamic effects of combined treatment with metformine and rosiglitasone (avandium) in patients with diabetes mellitus type 2 and high cardiovascular risk].
    Demidova TIu; Erokhina EN
    Ter Arkh; 2007; 79(10):39-45. PubMed ID: 18154144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microalbuminuria as a marker of cardiovascular risk in patients with type 2 diabetes.
    Erdmann E
    Int J Cardiol; 2006 Feb; 107(2):147-53. PubMed ID: 15975669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dynamics of structural-functional parameters of cardiovascular system during use of complex therapy of women with type 2 diabetes mellitus].
    Onuchin SG; Elsukova OS; Solov'ev OV; Onuchina EL
    Kardiologiia; 2010; 50(5):29-35. PubMed ID: 20831045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
    Betteridge DJ; Vergès B
    Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Glucose-independent impact of the glitazones on the cardiovascular outcome].
    Hanefeld M
    MMW Fortschr Med; 2005 Jan; 147(1-2):37-9. PubMed ID: 15704569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Glitazones critically evaluated].
    Schernthaner G
    Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
    [No Abstract]   [Full Text] [Related]  

  • 18. Is gliclazide a sulfonylurea with difference? A review in 2016.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):839-51. PubMed ID: 26924475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care.
    Hippisley-Cox J; Coupland C
    BMJ; 2016 Jul; 354():i3477. PubMed ID: 27413012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone: a review of its use in type 2 diabetes mellitus.
    Waugh J; Keating GM; Plosker GL; Easthope S; Robinson DM
    Drugs; 2006; 66(1):85-109. PubMed ID: 16398569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.